These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 1451522)
1. Ovarian activity and bleeding patterns during extended continuous use of a combined contraceptive vaginal ring. Davies GC; Feng LX; Newton JR; Dieben TO; Coelingh-Bennink HJ Contraception; 1992 Sep; 46(3):269-78. PubMed ID: 1451522 [TBL] [Abstract][Full Text] [Related]
2. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Mulders TM; Dieben TO Fertil Steril; 2001 May; 75(5):865-70. PubMed ID: 11334895 [TBL] [Abstract][Full Text] [Related]
3. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel. Davies GC; Feng LX; Newton JR; Van Beek A; Coelingh-Bennink HJ Contraception; 1993 Mar; 47(3):251-61. PubMed ID: 8462316 [TBL] [Abstract][Full Text] [Related]
4. The effects of a combined contraceptive vaginal ring releasing ethinyloestradiol and 3-ketodesogestrel on vaginal flora. Davies GC; Feng LX; Newton JR; Dieben TO; Coelingh-Bennink HJ Contraception; 1992 May; 45(5):511-8. PubMed ID: 1623721 [TBL] [Abstract][Full Text] [Related]
5. Contraception with a vaginal ring releasing 3-keto desogestrel and ethinylestradiol. Olsson SE; Odlind V Contraception; 1990 Nov; 42(5):563-72. PubMed ID: 2272184 [TBL] [Abstract][Full Text] [Related]
6. Extended regimens of the contraceptive vaginal ring: a randomized trial. Miller L; Verhoeven CH; Hout Ji Obstet Gynecol; 2005 Sep; 106(3):473-82. PubMed ID: 16135576 [TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of a contraceptive vaginal ring releasing 3-keto-desogestrel. Jackson R; Newton JR Contraception; 1989 Jun; 39(6):653-64. PubMed ID: 2752753 [TBL] [Abstract][Full Text] [Related]
9. [The desogestrel-ethinyl estradiol combination and overweight: current data]. Rubio Lotvin B Ginecol Obstet Mex; 1995 Nov; 63():483-6. PubMed ID: 8537039 [TBL] [Abstract][Full Text] [Related]
10. Clinical performance and endocrine profiles of contraceptive vaginal rings releasing 3-keto-desogestrel and ethinylestradiol. Apter D; Cacciatore B; Stenman UH; Alapiessa U; Assendorp R Contraception; 1990 Sep; 42(3):285-95. PubMed ID: 2149697 [TBL] [Abstract][Full Text] [Related]
11. Phase II dose-finding study on ovulation inhibition and cycle control associated with the use of contraceptive vaginal rings containing 17β-estradiol and the progestagens etonogestrel or nomegestrol acetate compared to NuvaRing. Duijkers I; Klipping C; Heger-Mahn D; Fayad GN; Frenkl TL; Cruz SM; Korver T Eur J Contracept Reprod Health Care; 2018 Aug; 23(4):245-254. PubMed ID: 30203681 [TBL] [Abstract][Full Text] [Related]
12. Comparison of uterine concentrations of ethinyl estradiol and etonogestrel after use of a contraceptive vaginal ring and an oral contraceptive. Roumen FJ; Dieben TO Fertil Steril; 2006 Jan; 85(1):57-62. PubMed ID: 16412731 [TBL] [Abstract][Full Text] [Related]
13. Extended regimens of the vaginal contraceptive ring: cycle control. Guazzelli CA; Barreiros FA; Barbosa R; de Araújo FF; Moron AF Contraception; 2009 Nov; 80(5):430-5. PubMed ID: 19835716 [TBL] [Abstract][Full Text] [Related]
14. Extended regimens of the contraceptive vaginal ring versus hormonal oral contraceptives: effects on lipid metabolism. Guazzelli CA; Barreiros FA; Barbosa R; Torloni MR; Barbieri M Contraception; 2012 Apr; 85(4):389-93. PubMed ID: 22067754 [TBL] [Abstract][Full Text] [Related]
16. Comparative study on the efficacy and acceptability of two contraceptive pills administered by the vaginal route: an international multicenter clinical trial. Coutinho EM; de Souza JC; da Silva AR; de Acosta OM; Alvarez F; Brache V; Garza Flores J; Vasquez-Estrada L; Santo R; Bassol S Clin Pharmacol Ther; 1993 Jan; 53(1):65-75. PubMed ID: 8422744 [TBL] [Abstract][Full Text] [Related]
17. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol. Akerlund M; Røde A; Westergaard J Br J Obstet Gynaecol; 1993 Sep; 100(9):832-8. PubMed ID: 8218004 [TBL] [Abstract][Full Text] [Related]
18. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation. Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763 [TBL] [Abstract][Full Text] [Related]
19. Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters. Jung-Hoffmann C; Fitzner M; Kuhl H Horm Res; 1991; 36(5-6):238-46. PubMed ID: 1823082 [TBL] [Abstract][Full Text] [Related]
20. Effects of a single contraceptive Silastic implant containing nomegestrol acetate on ovarian function and cervical mucus production during 2 years. Barbosa I; Coutinho E; Hirsch C; Ladipo O; Olsson SE; Ulmsten U Fertil Steril; 1996 Apr; 65(4):724-9. PubMed ID: 8654629 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]